Movers and SHAKERS
Onconova Therapeutics Inc. (ONTX)
Q4 2019 Earnings: INSPIRE Topline Data is on Track for H2 2020
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
INSPIRE study enrollment is completed, up next topline data readout. Onconova’s main focus has been its pivotal INSPIRE study, assessing rigosertib in 2nd-line high-risk myelodysplastic syndrome (HR-MDS) patients. Enrollment is complete (360 patients). The topline data is anticipated in H2 2020.
Competitive position of rigosertib in MDS. The evolution of MDS landscape is following AML's footprints (shifting from clinical definition of disease subsets to genetic or biomarker-related segmentation). We think there is room for multiple approvals. Rigosertib continues to represent an advanced and promising program in this competitive landscape. We believe investors will remain cautious until overall survival data from INSPIRE becomes available. However, we believe the company’s Phase 2/3 clinical trial initiation in 1st line MDS and...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.